Welcome

Susie Lisa
Vice President, Investor Relations
Safe Harbor for Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like anticipate, expect, project, believe, plan, estimate, intend and similar
words. These forward-looking statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees of future events or
performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could differ materially from the expectations and projections expressed or implied
by our forward-looking statements.

Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed
or to be filed with the Securities and Exchange Commission under the headings Risk Factors and Safe
Harbor for Forward-Looking Statements. Accordingly, you are cautioned not to place undue reliance on
any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our expectations or in events, conditions, or
circumstances on which they may be based, or that may affect the likelihood that actual results will differ
from those contained in the forward-looking statements.
 Regulatory Disclaimers

Product Regulatory Disclaimer

AXIOSTM Gallbladder and Bile Duct Drainage indications Europe only. Not available for use or sale in the U.S.
SpyGlassTM Next Gen Device under development. Not available for use or sale worldwide.
LithoVue Next Gen
TM Device under development. Not available for use or sale worldwide.
GUIDE DBS System CE Marked. Not available for use or sale in the U.S.
CE Marked. US: Caution: Investigational Device. Limited by Federal (or US) law to
Vercise Deep Brain Stimulation System
investigational use only. Not available for sale.
Vercise PC Deep Brain Stimulation System CE Marked. Not available for use or sale in the U.S.
Vercise Directional System CE Marked. Not available for use or sale in the U.S.
Vercise Gevia DBS System CE Marked. Not available for use or sale in the U.S.
SCS & DBS Next Gen Devices under development. Not available for use or sale worldwide.
HV / TACHY MRI Conditional Labeling CE Marked. Not available for use or sale in the U.S.
Leadless Pacemaker, EMPOWER TM Modular Pacing System, Emblem Pace Device under development. Not available for use or sale worldwide.
Implantable Cardiac Monitor Device under development. Not available for use or sale worldwide.
DirectSense TM Technology Device under development. Not available for use or sale worldwide.
Force Sensing Technology Device under development. Not available for use or sale worldwide.
IntellaNav TM MiFi OI AF ablation catheter Pending CE Mark. Not available for use or sale in the U.S.
 Regulatory Disclaimers
Product Regulatory Disclaimer
CE Marked. US: Caution: Investigational Device. Limited by Federal (or US) law to
RangerTM Drug-Coated Balloon
investigational use only. Not available for sale.
Drug-Coated Balloon, Drug Eluting Stent Below-the-knee indication Device under development. Not available for use or sale worldwide.
Next Gen Embolics Device under development. Not available for use or sale worldwide.
CE Marked. US: Caution: Investigational Device. Limited by Federal (or US) law to
EluviaTM Drug eluting self-expanding SFA stent
investigational use only. Not available for sale.
CE Marked. US: Caution: Investigational Device. Limited by Federal (or US) law to
Embozene TANDEMTM Drug Eluting Microspheres
investigational use only. Not available for sale.
OncozeneTM / EmbozeneTM Microspheres Not indicated for use as drug-eluting microspheres.
AngioJet ZelanteDVTTM Catheter Pulmonary Embolism indication Outside current device labeling.
Lotus Valve System Not available for use or sale worldwide.
Lotus EdgeTM Not available for use or sale worldwide.
Lotus Next Gen Device under development. Not available for use or sale worldwide.
CE Marked. US: Caution: Investigational Device. Limited by Federal (or US) law to
ACURATETM Self Expanding Valve Platform
investigational use only. Not available for sale.
ACURATE neoTM AS Valve System Pending CE Mark. Not available for use or sale in the U.S.
Mitral Valve technologies Devices under development. Not available for use or sale worldwide.
Tricuspid technologies Devices under development. Not available for use or sale worldwide.
WATCHMANTM FLX Pending CE Mark. Not available for use or sale in the U.S.
WATCHMANTM FLX Next Gen Device under development. Not available for use or sale worldwide.
High Definition IVUS catheter Device under development. Not available for use or sale worldwide.
Agenda
Time Topic Presenter
7:30am Welcome Susie Lisa

7:35am Strategic Overview Mike Mahoney

7:55am MedSurg
Dave Pierce, Art Butcher, Maulik Nanavaty
9:00am MedSurg Q&A
9:15am Rhythm Management
Joe Fitzgerald, Ken Stein, M.D.
9:45am Rhythm Management Q&A
10:00am Break
Jeff Mirviss, Kevin Ballinger, Nick-Spadea-Anello,
10:10am Cardiovascular
Ken Stein, M.D., Ian Meredith, M.D.
11:35am Financial Overview Dan Brennan
11:55am Q&A All Topics All
12:55pm Wrap up Mike Mahoney
1:00pm Box lunch with management team until 1:30pm
Opening Video
Financial Disclaimers
Market Estimates:

Unless noted otherwise, all references to market sizes, market share positions, and market growth rates are BSX internal estimates.

Non-GAAP Financial Measures:

For reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to the addendum to this presentation
and the Investor Relations section of our website at www.bostonscientific.com.
Constant Currency Measures:

Operational Revenue and growth are at constant currency and exclude divested businesses. References to constant currency are based on internally-
derived standard currency exchange rates, which may differ from year to year. Standard currency rates changed in January 2017, however, we have
not restated constant currency measures for the prior period and are using internally-derived standard currency exchange rates in place during the
referenced period.

Adjusted Operating Margin and Earnings Per Share (EPS) Measures:

Adjusted operating margin, adjusted earnings per share, and adjusted earnings per share excluding changes in foreign currency exchange rates are
non-GAAP and exclude goodwill and other intangible asset impairment charges, acquisition and divestiture-related net charges, litigation-related
charges, restructuring and restructuring-related charges, debt extinguishment charges, pension termination charges, discrete tax items, amortization
expense and/or changes in foreign currency exchange rates.
Adjusted Free Cash Flow Measures:

Adjusted Free Cash Flow excludes any potential amounts related to acquisition-, divestiture- and litigation-related items, significant tax audit settlements
and restructuring and restructuring-related items.
Strategy Overview
Mike Mahoney
Chairman & CEO
Our Mission and Values

Boston Scientific is dedicated

to transforming lives through
innovative medical solutions
that improve the health
of patients around the world.

Meaningful High Global

Caring Diversity Winning Spirit
Innovation Performance Collaboration
What to Expect from BSX

1. Living BSX values

2. Driving category leadership and expanding globally

3. Enhancing long term outlook by entering into multiple large and high growth markets

4. Consistently delivering revenue and adjusted EPS growth in top tier of peer group

5. Building shareholder value with disciplined capital allocation strategy

Track Record of Delivering High Performance

Operational
Adj. Operating Margin* Adj. EPS Growth*
Revenue Growth*
Organic revenue growth* Includes foreign exchange impact*
Operational revenue growth* Excludes foreign exchange impact*
(~$0.10 in 2015, ~$0.06 in 2016)

24.1% 26%
+26%
$8.4B
+12%
23% +23%
22.3%
12%

$7.5B +20%
8%
+10% 20.2%
$7.4B +8% +15%
18.9%
+6%
17.8% +11% +11%
+5%
$7.1B
+4%
$7.2B +2%

2012 2013 2014 2015 2016 2012*** 2013 2014 2015 2016 2012 2013 2014 2015 2016
-3% ***Adjusted for estimated impact of Medical Device Tax -2%
(~100bps), based on actual 2013 impact

Consistent double-digit
Strong, consistent sales growth ~630 bps adj. OM expansion
adjusted EPS growth*
Boston Scientific At-A-Glance: 2016
FY16 reported revenue and operational growth* (total company: $8.4B, +12%)

Interventional
Endoscopy
Cardiology
$2.3B, +13% $1.4B, +10%

Urology and
Structural Heart
Pelvic Health
$200M+ $1.0B, +14%*
(growth ex. AMS)

Peripheral
Neuromodulation
Interventions
$1.0B, +12% $560M, +12%

Rhythm Management
CRM Electrophysiology
$1.9B, +3% $245M, +5%
Strategic Imperatives Align Our Global Execution
STRENGTHEN EXPAND into High DRIVE FUND BUILD
Category Growth Global the Journey Stronger
Leadership Adjacencies Expansion to Fuel Growth Capabilities

Digital Health
Innovation driving Accelerating growth Building scale and Health Economics
Increase adjusted
growth faster via diversification into capabilities, targeting Advantics
operating margin* to
than peers in large faster growth Emerging Markets Patient awareness
~28% in 2020
global markets segments growth +15% Commercial
excellence
Competing & Innovating in Faster Growth Markets

2016E 16 - 20E
2016E 2020E
Business Market Market Key Investment Areas, New Markets
Market Size Market Size
Growth CAGR
Cardiovascular

Cardiology $7.5B 1% $8B 0-2% Complex PCI, PCI Guidance, Heart Failure

Structural Heart $3B 35% $6B 20% TAVR, LAAC, Mitral Replace & Repair

Peripheral $6B 7% $7.5B 6-8% Drug-eluting, Oncology, Venous, CLI

CRM + Diagnostics $10B 1% $10.5B 0-2% S-ICD/Leadless, Diagnostics, Heart Failure

Rhythm
Mgmt.

EP $4.5B 12% $6.5B 10-12% Mapping, Navigation, Therapeutic Solutions

Endoscopy $3B 5% $3.5B 5-6% Visualization, Pulmonary, Oncology, Endoluminal surgery

MedSurg

Urology & PH $3.5B 5% $4.5B 5-6% Stone, Prostate Health, ER, Globalization

Neuromod $2.5B 10% $3.5B 8-12% Pain, Brain, Movement Disorders

WW Total ~$40B 4-5% ~$50B 5-6% Continuing to invest in higher growth segments
Strong Culture of Delivering Meaningful Innovation
Research & Development
Higher R&D investment as % sales than peers
Leveraging R&D synergies between divisions
Expanding BSX global R&D capabilities in EM*
Community of Innovation
BSX Imagine If drives employee engagement
Evolving our BSX culture of innovation with recognition
Open innovation digital health competitions, partnering
with Google
Global Strategic Partnerships
Multiple incubators & external partnerships
Venture investments in Israel & China
IBM Research and other partnerships
Business Development
Successful BD track record over past 5 years
Active venture capital fund:
~30 investments in mixed stages of opportunity
*EM = Emerging Markets
Innovation that Delivers Real Economic Value
Selected examples:
NHS ~6M saving in 5 years by reducing avoidable CRT-D replacements2
1 Estimated to save U.S. Healthcare System ~$300M in 2015 & 2016 1

Potential $15B reduction in U.S. Heart Failure hospitalization costs in

2 BSX ICD/CRT-D patients3

Reduces risk of stroke & bleeding with quality of life benefits compared to warfarin
3 Provides overall healthcare cost savings compared to warfarin at 10 years4

32% decrease in asthma exacerbations & reduction in associated hospitalizations;

4 discounted 5-year cost of $28K vs. omalizumab $117K5,6,7,8

Lowers ureteroscope operating costs by $500+ and Operating Room costs by up to

5 $375 per case9
ADVANTICS Solutions:
Enhancing Category Leadership
Partners

Performance
Capital Financing Service Development Managed Services Disease Management
Optimization

Turnkey setup & Care process Patient referral Managed cath Care variation and
equipment improvement management labs & ORs standardization
financing opportunities
Supply chain Growth advisory Materials
Maintenance & optimization management Heart Failure
servicing financing patient support

Standardize HF
Improve Increase patient
Share risks and care to improve
Upgrade facilities operational access to
accountability outcomes and
effectiveness therapies
reduce costs
Strengthening Growth via Portfolio Diversification

Estimated Market Growth Rates

High Growth Mkt (>7% CAGR): TAVR, LAAC, EP, SCS, DBS, PI Drug-Eluting, Venous, HF Diagnostics
Moderate Growth Mkt (4 - 6% CAGR): Endo, Complex PCI, Oncology, Urology, Womens Health
Low Growth Mkt (0 - 3% CAGR): Pacer, Defibrillators, DES

2012 Revenue Mix 2016 Revenue Mix 2020E Revenue Mix

$7.2B $8.4B

Low Low High Low

High
Growth Growth
Growth Growth Growth
46% 37% 25% 25%
13%
Moderate
Moderate Moderate
Growth
High Growth
47% Growth
Growth 50%
50%
7%
Expanding into Multiple High Growth Adjacencies
That Will Approach ~$13B in 2020
BSX 2016 Market Growth Accelerators
Sales 2020E
LOTUS - TAVR
IC: TAVR + LAAC $200M+ $5B ACURATE - TAVR
WATCHMAN global expansion

Eluvia - DES
PI Drug Eluting ~$25M $2B Ranger DCB
Critical Limb Ischemia (CLI)

Heart Failure
RM Diagnostics --- $1B ICM

Pathology
Endo new markets ~$50M $2B Infection
Endo-luminal surgery

Visualization
Uro new markets ~$50M $2B Cancer
Overactive bladder

Vercise Brain
Neuromod - Brain ~$25M $1B Other indications 2020+

~$0.3B ~$13B
Significant New Launches + Core Portfolio Cadence

2017E 2018E 2019E 2020E-2021E

IC IC IC IC
LOTUS Edge EU Q4:17 LOTUS Edge U.S. WATCHMAN FLX Next ACURATE neo TF
ACURATE TAVR OUS mid-18 Gen LAAC EU U.S./Japan
CRM ACURATE OUS WATCHMAN - Japan LOTUS Next Gen EU
Expansion WATCHMAN FLX Next
Resonate HV MRI U.S. LOTUS Japan
Gen LAAC U.S.
EP ACURATE neo AS EU PI PI
RHYTHMIA HDX WW CRM Eluvia SFA DES - U.S. Ranger SFA DCB U.S.
NMD Resonate MRI & DES BTK WW
I/O Embolic Coils - WW
Gevia DBS MRI & Dir. HeartLogic HF Alert CRM/EP
Lead EU CRM/EP
WW Leadless Pacing &
Vercise DBS U.S. EP ICM Monitoring & Dx
Modular CRM EU
WW
DirectSense Rx Force Sensing Afib
Catheter EU/U.S. (EP) Force Sensing Afib Catheter U.S.
Catheter EU Endo
Endo Axios Transluminal Stent
SpyGlass Next Gen WW Japan
Uro NMD
SCS & DBS Next Gen
LithoVue Next Gen WW
U.S./EU
Emerging Markets to Drive ~150bps/Growth

Emerging Markets1 Emerging Markets1 Growth Emerging Markets1

Revenue* Drivers & Key Capabilities Partnerships
$1.4B Global orientation Partnerships & VC Investments
Portfolio registration, new launches
New R&D and physician training
$900M capabilities
New Malaysia manufacturing plant
$625M
Equity investments in key countries
Shift to minimally invasive
Tsinghua
techniques University

Latin America: Expanding access

2013 2017E* 2020E*

*Forecast years at standard FX rates
 Our Winning Spirit

PEOPLE 23,000 volunteer

hours
Forbes Americas Best
Employers
150+ Global FORTUNE Worlds Most
STEM events
Admired Companies

Reduced greenhouse Achieved 78%

gas emissions by 11k
Recycled 8k tons of
recycle index
21stgreenest
PLANET
solid waste company in the U.S.
by Newsweek

120 Close the Gap

100% on Corporate
health equity sites
Equality Index for LGBT
Top supporter of Inclusiveness

PRACTICES
Historically Black 100% on Disability
Colleges and Equality Index
Universities
References
* Non-GAAP measure; for reconciliations of non-GAAP financial measures to the most directly comparable GAAP figures, please refer to
Appendix A of this document
Slide 9 (Innovation that Delivers Real Economic Value)
1. Our modeling shows that in 2015 and again in 2016, our EnduraLife Battery Technology saved the U.S. Healthcare System approximately $300 million a
number quantified by using an average reimbursement value for outpatient ICD replacements that were avoided because of our long-lasting devices.
Source: Stein, Ken. Beckers Hospital World August 2016.

2. The National Institute of Health and Care Excellence (NICE) have recommended Boston Scientifics ENDURALIFE-powered CRT-D devices, following an
evaluation by their Medical Technologies Evaluation Committee (MTEP): From its evaluation of submitted evidence, NICE concluded that the extended battery
life observed with ENDURALIFE -powered CRT-Ds is likely to reduce the number of avoidable replacement procedures a patient may have to undergo, thereby
offering improved outcomes for patients and potential savings to the NHS of approximately 6 million in the first five years.
Source: MTG 294. NICE medical technology guidance: ENDURALIFE-powered CRT-D devices for treating heart failure. March 2017

3. $6 Billion in US healthcare system costs are driven by HF hospitalizations of patients with implanted ICDs or CRT-Ds. HeartLogic can detect 70% of these
hospitalization events a median of 34.5 days in advance of hospitalization, allowing care teams enough time to change therapy and reduce admissions.

4. Reddy VY, Akehurst RL, Armstrong SO, et al. Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure. J
Am Coll Cardiol. 2015;66(24):2728-39.

5. Castro et al. 2010 AJRCCM. Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma.

6. Cox et. al. 2007 NEJM. Asthma Control during the Year after Bronchial Thermoplasty.

7. Pavord et al. 2007 Ann Allergy Asthma Immunol. Safety of bronchial thermoplasty in patients with severe refractory asthma.

8. Zafari et al. 2016 PLoS One. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.

9. Results dependent on facility specific characteristics and does not represent all possible scenarios.

Slide 14 (Emerging Markets Focus to Drive ~150bps/Growth)

1. We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare
sectors, and our global capabilities. Currently, we include 20 countries in our definition of Emerging Markets